Mucolipidosis Type IV (ML4) Foundation
Research ServicesGeorgia, United States2-10 Employees
The Mucolipidosis Type IV (ML4) Foundation operates within the research services landscape, funding and supporting medical and scientific work aimed at developing treatments for ML4, a rare autosomal lysosomal disease. Its focus encompasses basic disease mechanisms as well as translational efforts in small molecule discovery, gene therapy, and clinical research, addressing the needs of children who experience severe neurological complications and vision loss. Based in Atlanta, Georgia, the organization targets researchers and clinicians dedicated to ML4 science and therapeutic development, serving as a catalyst for collaboration and progress in this niche field. As a small entity, it maintains a concentrated mission around advancing understanding and potential interventions for ML4, outlining a role that complements broader rare-disease research efforts without describing any specific funding or financial details. A recent development noted is the ongoing emphasis on supporting varied research approaches, including gene therapy and clinical studies, within its strategic focus on ML4.
1-888-653-2347 
support@leadiq.com 
